Baby boomers with disposable income are searching for the proverbial fountain of youth. These consumers, and others who have the desire to improve their quality of life, are looking for curative powers from select pharmaceuticals.
Hair loss, too much hair, wrinkles, erectile dysfunction — while unpleasant and, at times, inconvenient — are not life-threatening conditions. Yet pharmaceutical products associated with treating these conditions are growing in popularity and creating a conundrum for the pharmaceutical companies that manufacture and market them.
Although not an official or collective therapeutic class, pharmaceuticals that are used to improve quality of life, as opposed to treating a critical or chronic disease, are referred to as “lifestyle” drugs or “vanity” drugs. They are used to treat diseases often associated with normal aging. (A report from Business Insights also puts depression and obesity in this group, although these conditions can be life threatening under certain circumstances.)
Sales of Selected Lifestyle Drugs
Experts on this topic
Patrick Angelastro. Senior VP, Strategic Development, ImpactRx Inc., Mount Laurel, N.J.; ImpactRx is an information services organization that measures the direct impact of promotion on patient treatment as it occurs. For more information, visit impactrx.com.
Shelagh Brooke. Executive VP, Chief Strategic Officer, Quantum, part of CommonHealth, Parsippany, N.J.; CommonHealth is a network of 13 best-in-class specialized healthcare marketing companies. For more information, visit commonhealth.com.
Robert Goldberg, Ph.D. VP and Director of Programs, Center for Medicine in the Public Interest, New York; CMPI is a clearinghouse for up-to-the-minute facts on the development, accessibility, and safety of pharmaceuticals. For more information, visit cmpi.org.
David Kweskin. Senior VP, Practice Area Leader, Advertising and Brand Performance, TNS Healthcare, Teaneck, N.J.; TNS Healthcare, which is part of TNS, provides globally consistent solutions and custom advisory services to support product introductions, brand treatment, and sales-performance optimization, as well as professional and DTC promotional tracking. For more information, visit tns-global.com.
Paul LeVine. VP, Analytic Services, InfoMedics Inc., Woburn, Mass.; InfoMedics provides patient-physician communications programs for the pharmaceutical industry. For more information, visit infomedics.com.
Kristin Patton. Senior VP, Strategic Services, HealthEd, Clark, N.J., HealthEd develops strategic patient-education programs for pharmaceutical and healthcare marketers. For more information, visit healthed.com.
Jill Rogers. Director, Marketing Research Services, AllPoints Research Inc., Winston-Salem, N.C.; AllPoints Research is a full-service marketing research firm that employs state-of-the-art quantitative and qualitative techniques to deliver accurate, prompt, and insightful results. For more information, visit allpoints.biz.
Ed Wise. President and CEO, Cline, Davis & Mann Inc., New York; CDM is a full-service pharmaceutical advertising agency providing a wide range of marketing, educational, media, and creative services directed at healthcare professionals, providers, and business-to-business targets. For more information, visit clinedavis.com.
Chris Wright. Managing Principle and Practice Area Leader, Pharmaceuticals, ZS Associates, Evanston, Ill.; ZS Associates is a global management consulting firm specializing in sales and marketing strategy, operations, and execution. For more information,visit zsassociates.com.